You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Non-invasive Detection of Cerebral Aneurysm Recurrence after Endovascular Treatment Using Automated Image ProcessingSBC: Medical Innovators Company, LLC Topic: 101
PROJECT SUMMARY Hemorrhage due to cerebral aneurysm rupture is a devastating condition with high mortality. For the more than 30,000 patients in the US who are diagnosed annually with an aneurysm, treatment consists of preventing rupture, and increasingly relies of endovascular techniques. However, treatment durability is unknown with recurrence estimated at 16-40% and the re-treatment of 10-20%. ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: RASHMIVU LLC Topic: N
Summary Worldwide, only 1 out of 70 patients with corneal endothelial dystrophies and injuries receive a corneal transplant due to the limited corneal donor pool, the need for advanced surgical facilities and talent, and expense. RashmiVu is developing a stem cell based regenerative technology that addresses this large unmet global need through a paradigm shift, wherein treatment could be as simpl ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Viewpoint Therapeutics, Inc. Topic: NEI
Open-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: PELICAN THERAPEUTICS, INC. Topic: NIAID
PROJECT SUMMARY Graft-vs-Host-Disease (GVHD) is a frequent and life-threatening complication of hematopoietic stem cell transplantation (HSCT), a procedure that often represents the best treatment option for patients suffering from hematological malignancies. Even when HLA-matched family or unrelated donors are available, an unsatisfactorily high frequency (30-40%) of transplant recipients still d ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Lassogen, Inc. Topic: NCCIH
Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
Rapid Assessment of Drug Abuse from Municipal Wastewater by Smart Surface-Enhanced Raman Scattering TechniqueSBC: E-Lambda LLC Topic: NIDA
Rapid Assessment of Drug Abuse from Municipal Wastewater by Smart Surface-Enhanced RamanScattering Technique PROJECT SUMMARY Rapid assessment of drug abuse from municipal wastewater is a new strategy that can overcome many limitations of traditional surveillance technologies by providing a more rapid and objective measure of drug use, which can alert communities about raising problems in their ear ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: M&S Biotics, Inc. Topic: NCATS
PROJECT SUMMARY / ABSTRACT Prolonged operative times are associated with significant patient morbidity and mortality, and multiple studies have quantified the degree to which prolonged operative time increases a patientandapos;s risk of adverse complications, like infections. Similarly, ineffective asset management in the OR leads to inefficient utilization of resources and may contribute to prolo ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Technology Commercialization Partners LLC Topic: NHLBI
ABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: SEACOAST SCIENCE, INC. Topic: NIEHS
Perfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate) are toxic and persistent compounds resulting from the production and use of fluoropolymers such as Gortex® and Teflon ®. The structure of PFAS preclude environmental degradation and can lead to bioaccumulation in animals and humans. Reported adverse effects of these compounds in humans include: ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: ProteoWise Inc. Topic: NIA
Abstract For the extent of our careers as Alzheimer’s researchers, we have struggled with the limitations imposed by the standard techniques for protein analysis. Western blot, the go-to protein technology of the bench researcher, is no match for the complex brain protein distortions of AD. To remedy this debility, we devised a technology that we are making available to all researchers through t ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health